Does TREMELIMUMAB Cause Immune-mediated hepatitis? 51 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 51 reports of Immune-mediated hepatitis have been filed in association with TREMELIMUMAB (IMJUDO). This represents 2.1% of all adverse event reports for TREMELIMUMAB.
51
Reports of Immune-mediated hepatitis with TREMELIMUMAB
2.1%
of all TREMELIMUMAB reports
6
Deaths
22
Hospitalizations
How Dangerous Is Immune-mediated hepatitis From TREMELIMUMAB?
Of the 51 reports, 6 (11.8%) resulted in death, 22 (43.1%) required hospitalization, and 3 (5.9%) were considered life-threatening.
Is Immune-mediated hepatitis Listed in the Official Label?
Yes, Immune-mediated hepatitis is listed as a known adverse reaction in the official FDA drug label for TREMELIMUMAB.
What Other Side Effects Does TREMELIMUMAB Cause?
Pyrexia (178)
Diarrhoea (136)
Death (116)
Colitis (115)
Pneumonitis (87)
Pneumonia (85)
Sepsis (82)
Vomiting (78)
Febrile neutropenia (72)
Malignant neoplasm progression (68)
What Other Drugs Cause Immune-mediated hepatitis?
NIVOLUMAB (640)
PEMBROLIZUMAB (549)
IPILIMUMAB (443)
CARBOPLATIN (213)
PACLITAXEL (167)
ATEZOLIZUMAB (142)
BEVACIZUMAB (108)
DURVALUMAB (90)
LENVATINIB (86)
PEMETREXED (86)
Which TREMELIMUMAB Alternatives Have Lower Immune-mediated hepatitis Risk?
TREMELIMUMAB vs TREMELIMUMAB\TREMELIMUMAB-ACTL
TREMELIMUMAB vs TRENBOLONE
TREMELIMUMAB vs TREOSULFAN
TREMELIMUMAB vs TREPROSTINIL
TREMELIMUMAB vs TREPROSTINIL DIOLAMINE